The MEK inhibitors enhance the efficacy of sorafenib against hepatocellular carcinoma cells through reducing p-ERK rebound

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most common malignant tumours worldwide and has a poor prognosis. Sorafenib, the only targeted therapeutic agent for HCC, is a multiple kinase inhibitor with targets including RAF and VEGFR-2/3 that display a very limited ability to extend the...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Wanting, Xia, Hongwei, Zhou, Sheng, Fan, Zhenhai, Xu, Huanji, Gong, Qiyong, Nie, Yongzhan, Tang, Qiulin, Bi, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799119/
https://www.ncbi.nlm.nih.gov/pubmed/35116864
http://dx.doi.org/10.21037/tcr.2019.07.11

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799119/
https://www.ncbi.nlm.nih.gov/pubmed/35116864
http://dx.doi.org/10.21037/tcr.2019.07.11

Ejemplares similares